All In Biotech

Drug Trial Radar · NCT03771664

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia

Last checked: Nov 20, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

87

Actual

Start

Feb 4, 2019

Primary completion

Dec 20, 2019

Study completion Jan 17, 2020

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Dec 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.

Conditions

  • Major Depressive Disorder
  • Insomnia

Interventions

  • SAGE-217Drug

    Administered as capsules.

  • PlaceboDrug

    Administered as capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average Change From Baseline in Sleep Efficiency (SE) as Assessed by Polysomnogram (PSG) at Days 13 and 14Time frame: Baseline and Days 13, 14

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Sage Investigational Site

    Little Rock, Arkansas

  • Sage Investigational Site

    Rogers, Arkansas

  • Sage Investigational Site

    Garden Grove, California

  • Sage Investigational Site

    Oceanside, California

  • Sage Investigational Site

    San Diego, California

  • Sage Investigational Site

    Temecula, California

  • Sage Investigational Site

    Fort Myers, Florida

  • Sage Investigational Site

    Hollywood, Florida

  • Sage Investigational Site

    Miami Lakes, Florida

  • Sage Investigational Site

    North Miami, Florida

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Decatur, Georgia

  • Sage Investigational Site

    Chicago, Illinois

  • Sage Investigational Site

    Lake Charles, Louisiana

  • Sage Investigational Site

    Flowood, Mississippi

  • Sage Investigational Site

    St Louis, Missouri

  • Sage Investigational Site

    Las Vegas, Nevada

  • Sage Investigational Site

    Berlin, New Jersey

  • Sage Investigational Site

    Albuquerque, New Mexico

  • Sage Investigational Site

    Brooklyn, New York

  • Sage Investigational Site

    New York, New York

  • Sage Investigational Site

    Cincinnati, Ohio

  • Sage Investigational Site

    Dayton, Ohio

  • Sage Investigational Site

    Oklahoma City, Oklahoma

  • Sage Investigational Site

    Salem, Oregon

  • Sage Investigational Site

    Charleston, South Carolina

  • Sage Investigational Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.